We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Higher Thyroid Hormone Levels Linked to Sudden Cardiac Death

By LabMedica International staff writers
Posted on 21 Sep 2016
Print article
Image: The VITROS ECiQ immunodiagnostic system (Photo courtesy of Ortho-Clinical Diagnostics).
Image: The VITROS ECiQ immunodiagnostic system (Photo courtesy of Ortho-Clinical Diagnostics).
Thyroid hormone is made in the thyroid gland and circulates in the blood to help regulate nearly all of the body's organs, including the heart. Although the link between abnormal levels of thyroid hormone and cardiovascular disease is well established, the hormone's relationship with sudden cardiac death is unclear.

Thyroid hormone is known to increase heart rate, increase cardiac contractility, alter systolic and diastolic function, and decrease systematic vascular resistance. Thyroid dysfunction, even in the subclinical range, is associated with an increased incidence of cardiovascular risk factors and disease.

Scientists at the Erasmus University Medical Center (Rotterdam, The Netherlands) analyzed 10,318 patients in the Rotterdam Study, which is a long-term investigation of heart and other chronic disease among the middle-aged and elderly in the Netherlands. Participants' mean age was 65, more than half were women, and nearly all were Caucasian. They assessed the association of thyroid-stimulating hormone and FT4 with the risk of sudden cardiac death (SCD).

Thyroid-stimulating hormone (TSH) or free thyroxine (FT4) measurements were made at the baseline visit of the study cohorts. Serum TSH (TSH LUMItest; Brahms GmbH, Hennigsdorf, Germany) and FT4 levels (FT4; Vitros, ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, Raritan, NJ, USA) were determined in a random subset of the 1,855 baseline serum samples, thyroid function assessment was also performed in baseline serum samples for TSH and FT4 (the electrochemiluminescence immunoassay for thyroxine and thyrotropin, (ECLIA, Roche Diagnostics, Indianapolis, IN, USA).

The investigators found that participants with free thyroxine hormone levels at the high end of the normal range were 2.5 times more likely to die of sudden cardiac death, compared to patients with levels at the lower end. The ten-year risk of sudden cardiac death was four times greater among patients with higher free thyroxine levels compared to those with lower levels, 4% versus 1%. The increased risk persisted even after controlling for other risk factors, such as high cholesterol and high blood pressure and 261 cases of sudden cardiac death occurred.

Layal Chaker, MD, MSc, a doctoral candidate and lead author of the study, “Currently, we do not have a good way to predict sudden cardiac death in the general population. Thus identifying additional risk factors is crucial. Our results indicate that thyroid hormone levels may be useful for assessing risk to prevent sudden cardiac death. We know that a considerable proportion of patients on thyroid hormone replacement therapy are over-treated and so have high blood levels of thyroid hormone. Our study suggests more caution is warranted in the treatment of thyroid hormone replacement. Replacement therapy is often aimed at the high normal range which carries a risk of overtreatment.” The study was published on |September 6, 2016 in the journal Circulation.

Related Links:
Erasmus University Medical Center
Brahms
Ortho-Clinical Diagnostics
Roche Diagnostics
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.